Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia

Paolo Pedrazzoli, Giovanni Rosti, Simona Secondino, Salvatore Siena

Research output: Contribution to journalArticle

Abstract

Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.

Original languageEnglish
Pages (from-to)1169-1173
Number of pages5
JournalCancer
Volume115
Issue number6
DOIs
Publication statusPublished - Mar 15 2009

Keywords

  • Cancer anemia
  • Chemotherapy
  • Erythropoiesis-stimulatory agents
  • Iron supplementation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia'. Together they form a unique fingerprint.

  • Cite this